Literature DB >> 28077641

Chikungunya, Influenza, Nipah, and Semliki Forest Chimeric Viruses with Vesicular Stomatitis Virus: Actions in the Brain.

Anthony N van den Pol1, Guochao Mao2, Anasuya Chattopadhyay3, John K Rose3, John N Davis2.   

Abstract

Recombinant vesicular stomatitis virus (VSV)-based chimeric viruses that include genes from other viruses show promise as vaccines and oncolytic viruses. However, the critical safety concern is the neurotropic nature conveyed by the VSV glycoprotein. VSVs that include the VSV glycoprotein (G) gene, even in most recombinant attenuated strains, can still show substantial adverse or lethal actions in the brain. Here, we test 4 chimeric viruses in the brain, including those in which glycoprotein genes from Nipah, chikungunya (CHIKV), and influenza H5N1 viruses were substituted for the VSV glycoprotein gene. We also test a virus-like vesicle (VLV) in which the VSV glycoprotein gene is expressed from a replicon encoding the nonstructural proteins of Semliki Forest virus. VSVΔG-CHIKV, VSVΔG-H5N1, and VLV were all safe in the adult mouse brain, as were VSVΔG viruses expressing either the Nipah F or G glycoprotein. In contrast, a complementing pair of VSVΔG viruses expressing Nipah G and F glycoproteins were lethal within the brain within a surprisingly short time frame of 2 days. Intranasal inoculation in postnatal day 14 mice with VSVΔG-CHIKV or VLV evoked no adverse response, whereas VSVΔG-H5N1 by this route was lethal in most mice. A key immune mechanism underlying the safety of VSVΔG-CHIKV, VSVΔG-H5N1, and VLV in the adult brain was the type I interferon response; all three viruses were lethal in the brains of adult mice lacking the interferon receptor, suggesting that the viruses can infect and replicate and spread in brain cells if not blocked by interferon-stimulated genes within the brain.IMPORTANCE Vesicular stomatitis virus (VSV) shows considerable promise both as a vaccine vector and as an oncolytic virus. The greatest limitation of VSV is that it is highly neurotropic and can be lethal within the brain. The neurotropism can be mostly attributed to the VSV G glycoprotein. Here, we test 4 chimeric viruses of VSV with glycoprotein genes from Nipah, chikungunya, and influenza viruses and nonstructural genes from Semliki Forest virus. Two of the four, VSVΔG-CHIKV and VLV, show substantially attenuated neurotropism and were safe in the healthy adult mouse brain. VSVΔG-H5N1 was safe in the adult brain but lethal in the younger brain. VSVΔG Nipah F+G was even more neurotropic than wild-type VSV, evoking a rapid lethal response in the adult brain. These results suggest that while chimeric VSVs show promise, each must be tested with both intranasal and intracranial administration to ensure the absence of lethal neurotropism.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  Nipah virus; blood-brain barrier; brain; chikungunya; influenza virus; neurotropic viruses; vesicular stomatitis virus; viral vaccine

Mesh:

Substances:

Year:  2017        PMID: 28077641      PMCID: PMC5331823          DOI: 10.1128/JVI.02154-16

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  56 in total

1.  Complementing defective viruses that express separate paramyxovirus glycoproteins provide a new vaccine vector approach.

Authors:  Anasuya Chattopadhyay; John K Rose
Journal:  J Virol       Date:  2010-12-22       Impact factor: 5.103

2.  Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses.

Authors:  Maryam Ahmed; Scott D Cramer; Douglas S Lyles
Journal:  Virology       Date:  2004-12-05       Impact factor: 3.616

3.  Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity.

Authors:  Masatsugu Obuchi; Marilyn Fernandez; Glen N Barber
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

4.  Long-distance interferon signaling within the brain blocks virus spread.

Authors:  Anthony N van den Pol; Siyuan Ding; Michael D Robek
Journal:  J Virol       Date:  2014-01-15       Impact factor: 5.103

5.  Vesicular stomatitis virus-based vaccines protect nonhuman primates against aerosol challenge with Ebola and Marburg viruses.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Joan B Geisbert; Douglas S Reed; Friederike Feldmann; Allen Grolla; Ute Ströher; Elizabeth A Fritz; Lisa E Hensley; Steven M Jones; Heinz Feldmann
Journal:  Vaccine       Date:  2008-10-18       Impact factor: 3.641

6.  Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial.

Authors:  Ana Maria Henao-Restrepo; Ira M Longini; Matthias Egger; Natalie E Dean; W John Edmunds; Anton Camacho; Miles W Carroll; Moussa Doumbia; Bertrand Draguez; Sophie Duraffour; Godwin Enwere; Rebecca Grais; Stephan Gunther; Stefanie Hossmann; Mandy Kader Kondé; Souleymane Kone; Eeva Kuisma; Myron M Levine; Sema Mandal; Gunnstein Norheim; Ximena Riveros; Aboubacar Soumah; Sven Trelle; Andrea S Vicari; Conall H Watson; Sakoba Kéïta; Marie Paule Kieny; John-Arne Røttingen
Journal:  Lancet       Date:  2015-08-03       Impact factor: 79.321

Review 7.  Recombinant vesicular stomatitis virus as an HIV-1 vaccine vector.

Authors:  David K Clarke; David Cooper; Michael A Egan; R Michael Hendry; Christopher L Parks; Stephen A Udem
Journal:  Springer Semin Immunopathol       Date:  2006-09-15

8.  Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

Authors:  Julia V Cockle; Karishma Rajani; Shane Zaidi; Timothy Kottke; Jill Thompson; Rosa Maria Diaz; Kevin Shim; Tim Peterson; Ian F Parney; Susan Short; Peter Selby; Elizabeth Ilett; Alan Melcher; Richard Vile
Journal:  Neuro Oncol       Date:  2015-09-26       Impact factor: 12.300

9.  Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.

Authors:  Alexander Muik; Lawton J Stubbert; Roza Z Jahedi; Yvonne Geiβ; Janine Kimpel; Catherine Dold; Reinhard Tober; Andreas Volk; Sabine Klein; Ursula Dietrich; Beta Yadollahi; Theresa Falls; Hrvoje Miletic; David Stojdl; John C Bell; Dorothee von Laer
Journal:  Cancer Res       Date:  2014-05-08       Impact factor: 12.701

10.  Vesicular stomatitis virus-based ebola vaccine is well-tolerated and protects immunocompromised nonhuman primates.

Authors:  Thomas W Geisbert; Kathleen M Daddario-Dicaprio; Mark G Lewis; Joan B Geisbert; Allen Grolla; Anders Leung; Jason Paragas; Lennox Matthias; Mark A Smith; Steven M Jones; Lisa E Hensley; Heinz Feldmann; Peter B Jahrling
Journal:  PLoS Pathog       Date:  2008-11-28       Impact factor: 6.823

View more
  16 in total

1.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

2.  Mechanisms of Innate Immune Activation by a Hybrid Alphavirus-Rhabdovirus Vaccine Platform.

Authors:  Anthony M Marchese; Carolina Chiale; Safiehkhatoon Moshkani; Michael D Robek
Journal:  J Interferon Cytokine Res       Date:  2019-10-18       Impact factor: 2.607

3.  Mucin-Like Domain of Ebola Virus Glycoprotein Enhances Selective Oncolytic Actions against Brain Tumors.

Authors:  Xue Zhang; Tingting Zhang; John N Davis; Andrea Marzi; Anthony M Marchese; Michael D Robek; Anthony N van den Pol
Journal:  J Virol       Date:  2020-03-31       Impact factor: 5.103

Review 4.  Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

Authors:  Jonathan G Pol; Sarah Lévesque; Samuel T Workenhe; Shashi Gujar; Fabrice Le Boeuf; Derek R Clements; Jean-Eudes Fahrner; Laetitia Fend; John C Bell; Karen L Mossman; Jitka Fucikova; Radek Spisek; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2018-08-27       Impact factor: 8.110

5.  Pseudovirus rVSVΔG-ZEBOV-GP Infects Neurons in Retina and CNS, Causing Apoptosis and Neurodegeneration in Neonatal Mice.

Authors:  Ian L McWilliams; Jennifer L Kielczewski; Derek D C Ireland; Jacob S Sykes; Aaron P Lewkowicz; Krishnamurthy Konduru; Biying C Xu; Chi-Chao Chan; Rachel R Caspi; Mohanraj Manangeeswaran; Daniela Verthelyi
Journal:  Cell Rep       Date:  2019-02-12       Impact factor: 9.423

6.  Enhancing the Oncolytic Activity of CD133-Targeted Measles Virus: Receptor Extension or Chimerism with Vesicular Stomatitis Virus Are Most Effective.

Authors:  Dina Kleinlützum; Julia D S Hanauer; Alexander Muik; Kay-Martin Hanschmann; Sarah-Katharina Kays; Camilo Ayala-Breton; Kah-Whye Peng; Michael D Mühlebach; Tobias Abel; Christian J Buchholz
Journal:  Front Oncol       Date:  2017-06-26       Impact factor: 6.244

7.  Virus-like Vesicles Expressing Multiple Antigens for Immunotherapy of Chronic Hepatitis B.

Authors:  Timur O Yarovinsky; Stephen W Mason; Manisha Menon; Marie M Krady; Maria Haslip; Bhaskara R Madina; Xianyong Ma; Safiehkhatoon Moshkani; Carolina Chiale; Anasuya Chattopadhyay Pal; Bijan Almassian; John K Rose; Michael D Robek; Valerian Nakaar
Journal:  iScience       Date:  2019-10-24

Review 8.  Ebola virus disease.

Authors:  Shevin T Jacob; Ian Crozier; William A Fischer; Angela Hewlett; Colleen S Kraft; Marc-Antoine de La Vega; Moses J Soka; Victoria Wahl; Anthony Griffiths; Laura Bollinger; Jens H Kuhn
Journal:  Nat Rev Dis Primers       Date:  2020-02-20       Impact factor: 52.329

9.  Virus-Like Vesicles Based on Semliki Forest Virus-Containing Rabies Virus Glycoprotein Make a Safe and Efficacious Rabies Vaccine Candidate in a Mouse Model.

Authors:  Chengguang Zhang; Yuling Tian; Chen Chen; Zongmei Wang; Jie Pei; Chuhan Lin; Ming Zhou; Zhen F Fu; Ling Zhao
Journal:  J Virol       Date:  2021-08-04       Impact factor: 5.103

10.  Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.

Authors:  James Brett Case; Paul W Rothlauf; Rita E Chen; Natasha M Kafai; Julie M Fox; Brittany K Smith; Swathi Shrihari; Broc T McCune; Ian B Harvey; Shamus P Keeler; Louis-Marie Bloyet; Haiyan Zhao; Meisheng Ma; Lucas J Adams; Emma S Winkler; Michael J Holtzman; Daved H Fremont; Sean P J Whelan; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2020-07-30       Impact factor: 31.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.